Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses

Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses: Randomized Controlled Trial.

The withdrawal syndrome in benzodiazepines and morphine is common in intensive care, the incidence is estimated at 32.1%.

Cerebrospatized patients are probably more prone to withdrawal because they require high doses of sedation.

Moreover, this syndrome is probably deleterious on the cerebral hemodynamics (high point of the therapeutic management).

Inclusion Criteria:

• Major Patient
• Admitted in Neuroreanimation
• Cerebroséé (TC-HSA-AVC)
• Mono or multi failing
• After a neurosedation ≥ 3 days by hypnotic type benzodiazepine (Midazolam®) and morphinomimetic (Sufentanyl®) in IVSE
• Affiliation to Social Security
• Agreement of the person of confidence

Exclusion Criteria:

• Addiction to opiates, cocaine or cannabis
• Neurological Pathology Before Hospitalization
• Patient suffering from cardiac arrest
• Pregnant woman
• Sedation window
• Patient under tutelage or curatorship or deprived of public law